analyzeportfolio
Nasdaq · Healthcare

Privia Health Group, Inc. (PRVA)

As-reported financials and SEC filings for Privia Health Group, Inc. The latest annual period is FY2025. The latest reported quarter is Q2 FY2026. Financial statements come straight from the company’s EDGAR filings; valuation figures such as P/E and market cap use market data.

About Privia Health Group, Inc.

Privia Health Group, Inc. is a national physician-enablement company that partners with physician practices, health plans, and health systems to improve healthcare outcomes and reduce costs. It organizes physicians and clinicians into regional medical groups and provides technology and management services through its Privia Platform to support value-based care and optimize provider workflows. The company serves over 5,300 providers across 24 states and the District of Columbia, caring for more than 5.8 million patients.

Snapshot

Revenue
$2.12B
Revenue growth (YoY)
22.3%
Net income
$22.9M
Diluted EPS
$0.18
Gross margin
Operating margin
1.6%
Net margin
1.1%
FCF margin
ROE
2.9%
net income / fiscal-year-end equity
P/E
94.5×
trailing when available, otherwise FY EPS
Market cap
$2.66B
Long-term debt / equity
non-current term debt only

Fundamentals are from SEC filings for FY2025, the latest annual period (ended December 31, 2025). P/E and market cap are derived from stored market prices, last retrieved on a rolling basis and typically within the past week.

What changed at Privia Health Group

  • Revenue grew 22.3% to $2.1B in FY2025, faster than the 4.7% the year before.
  • Operating margin turned positive at 1.6% in FY2025, from a 22.5% operating loss in FY2021.
  • Most recent quarter Q2 FY2026: revenue $633M, up 21.4% from Q2 FY2025.
  • Net income rose 59.3% to $23M in FY2025.

Computed from the as-reported figures in the statements below. A change we cannot state from filed figures is left out rather than estimated.

Peer comparison

Where Privia Health Group’s fundamentals sit among the 558 Healthcare companies. Each figure is ranked only against peers that report it, from lowest (left) to highest (right).

Operating margin1.6%
52nd percentile of 399
Net margin1.1%
54th percentile of 418
Revenue growth (YoY)+22.3%
71st percentile of 538
ROE2.9%
64th percentile of 473
P/E94.5×
90th percentile of 201
Short interest3.41d
38th percentile of 557

Privia Health Group’s P/E of 94.5 ranks in the 90th percentile of the 201 peers with a meaningful P/E.

No reported insider purchases (code P) in the last 90 days; 11 insider sales totaling $12.2M. For context, about 15% of companies in the universe saw any reported insider purchase (code P) in the same window. Browse insider activity →

Percentiles describe where a figure sits among sector peers reporting it (100th = highest). They are position within a peer group, not a rating, and not investment advice. Short interest ranking uses days to cover from FINRA Consolidated Short Interest data; FINRA is the owner and source of that data, included at no additional charge.

Institutional ownership

Held by 1 of the superinvestors we track (plus 5 quant / multi-strat books), based on each investor’s most recent 13F; periods vary by investor (newest: Q2 2026).

Conviction investors
1
+5 quant / multi-strat
Initiated / added
2
0 new, 2 added
Reduced / exited
6
4 trimmed, 2 exited
Combined position
$41.3M
reported long value
InvestorAs ofPosition valueSharesChange
Renaissance TechnologiesquantQ2 2026$16.3M632.7KReduced
D. E. ShawquantQ2 2026$9.1M353.2KAdded
Millennium ManagementquantQ2 2026$6.9M268.3KReduced
AQR Capital ManagementquantQ2 2026$6.6M255.6KAdded
Citadel AdvisorsquantQ2 2026$1.3M48.8KReduced
Gotham Asset ManagementQ2 2026$1.2M46.8KReduced

No longer held by: Bridgewater Associates (as of Q2 2026), Point72 Asset Management (as of Q2 2026)

From quarterly Form 13F filings, which can be up to 45 days delayed. Long US-listed positions only: excludes short positions, options, cash, bonds, and non-US holdings, so this is not a manager’s complete portfolio. Counts are of the investors we track, not all institutions. Not investment advice.

Recent insider activity

Non-derivative buys and sells (codes P/S) reported by officers, directors and 10% owners on SEC Form 4.

Buys (90d)
0
code P
Bought (90d)
code P value
Sells (90d)
11
$12.2M
Reported activity
Net selling
by $ value, 90d
Trade dateInsiderTypeSharesPriceValue
2026-07-09
filed 2026-07-13
Mountcastle DavidEVP & Chief Financial OfficerSell21.3K$27.67$589K
2026-07-07
filed 2026-07-09
Mountcastle DavidEVP & Chief Financial OfficerSell600$27.57$17K
2026-07-06
filed 2026-07-07
Morris Matthew ShawnDirectorSell53.7K$27.24$1.5M
2026-07-02
filed 2026-07-07
Morris Matthew ShawnDirectorSell59.0K$27.33$1.6M
2026-07-02
filed 2026-07-07
Mountcastle DavidEVP & Chief Financial OfficerSell24.7K$27.50$680K
2026-07-01
filed 2026-07-02
Morris Matthew ShawnDirectorSell45.6K$26.52$1.2M
2026-07-01
filed 2026-07-02
Morris Matthew ShawnDirectorSell37.0K$26.93$998K
2026-06-30
filed 2026-07-02
Morris Matthew ShawnDirectorSell52.8K$25.72$1.4M
2026-06-29
filed 2026-06-30
Morris Matthew ShawnDirectorSell63.2K$25.33$1.6M
2026-06-26
filed 2026-06-30
Morris Matthew ShawnDirectorSell88.1K$25.33$2.2M
2026-06-26
filed 2026-06-30
Mountcastle DavidEVP & Chief Financial OfficerSell17.2K$25.18$433K
2026-05-12
filed 2026-05-13
Mehrotra ParthChief Executive OfficerSell15.6K$22.64$354K

Reported non-derivative purchases and sales (codes P/S) — which may be open-market or private; excludes option exercises, grants, and shares withheld for taxes. Dates shown are the trade date; a Form 4 can be filed days to years later. A sale can be routine (e.g. a pre-set 10b5-1 plan), so read individual transactions in context. From SEC Form 4. Not investment advice.

Short interest

Total shares sold short as of each twice-monthly FINRA settlement. Rising short interest means more investors are positioned against the stock; days to cover estimates how many trading days of average volume that position represents.

Shares short
5.3M
settled 2026-08-14
Change vs prior
+37.9%
vs previous settlement
Days to cover
3.41
at avg daily volume
Avg daily volume
1.5M
FINRA reported
SettlementShares shortChangeDays to cover
2026-08-145.3M+37.9%3.41
2026-07-313.8M+4.0%3.37
2026-07-153.7M-0.9%3.32
2026-06-303.7M+24.4%2.67
2026-06-153.0M-10.0%2.94
2026-05-293.3M-2.0%4.44
2026-05-153.4M+6.0%2.62
2026-04-303.2M+18.3%4.09

Source: FINRA Consolidated Short Interest. FINRA is the owner and source of the FINRA-supplied data, which is included at no additional charge for your own personal or professional use; republishing or redistributing it is not permitted. Settlement dates are shown; FINRA publishes each settlement about nine business days later, so the latest figure can be two to four weeks old. Not presented as a percentage of float. No FINRA endorsement of this product is implied. Not investment advice.

Income statement (as reported)

 FY2025FY2024FY2023FY2022FY2021
Revenue$2.12B$1.74B$1.66B$1.36B$966.2M
Gross profit
Operating income$34.2M$17.0M$20.6M$-19.1M$-217.4M
Net income$22.9M$14.4M$23.1M$-8.6M$-188.2M
Diluted EPS$0.18$0.11$0.19$-0.08$-1.83

Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (hover to see the figure as filed). Full details: where the numbers come from.

Balance sheet (as reported)

 FY2025FY2024FY2023FY2022FY2021
Cash and equivalents$479.7M$491.1M$389.5M$348.0M$320.6M
Current assets$911.0M$834.8M$700.8M$552.0M$446.7M
Total assets$1.37B$1.14B$999.9M$792.8M$686.4M
Current liabilities$568.5M$449.1M$387.0M$264.3M$190.5M
Long-term debt
Total liabilities$578.4M$452.3M$392.5M$273.8M$236.2M
Total equity$790.9M$683.4M$607.4M$519.0M$450.2M

Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (hover to see the figure as filed). Full details: where the numbers come from.

Cash flow (as reported)

 FY2025FY2024FY2023FY2022FY2021
Operating cash flow$163.4M$109.3M$80.8M$47.2M$55.1M
Capital expenditure$113,000$104,000$547,000
Free cash flow$80.7M$47.1M$54.5M

Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (hover to see the figure as filed). Full details: where the numbers come from.

Quarterly trend (as reported)

QuarterRevenueRevenue YoYNet incomeDiluted EPS
Q2 FY2026$632.6M21.4%$9.0M$0.07
Q1 FY2026$603.8M25.8%$3.1M$0.02
Q4 FY2025$541.2M17.4%$9.2M$0.07
Q3 FY2025$580.4M32.5%$6.9M$0.05
Q2 FY2025$521.2M23.4%$2.7M$0.02
Q1 FY2025$480.1M15.6%$4.2M$0.03
Q4 FY2024$460.9M4.6%$4.4M$0.03
Q3 FY2024$437.9M4.9%$3.5M$0.03

Latest 8 reported quarters, from company XBRL filings on SEC EDGAR.

Company facts

ExchangeNasdaq
SectorHealthcare
SIC industryServices-Health Services
Latest annual periodFY2025 (ended December 31, 2025)
Latest reported quarterQ2 FY2026 (ended June 30, 2026)
Oldest indexed filing2019
SEC CIK1759655

Selected SEC filings

10-Q2026-08-06
View on EDGAR →
10-Q2026-05-07
View on EDGAR →
8-K2026-08-18
View on EDGAR →
8-K2026-08-06
View on EDGAR →
8-K2026-07-07
View on EDGAR →
8-K2026-05-22
View on EDGAR →

Largest Healthcare peers

All Healthcare companies →

Monitor PRVA

Get an alert when Privia Health Group files something material, see which superinvestors own it, and ask its filings a question with cited answers.

Monitor PRVA free

Includes one free filing-grounded research answer. Or check your whole portfolio, no account needed.

Data sourced from SEC EDGAR. Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only. Not investment advice.